{"pmid":32502313,"title":"Emerging evidence to support not always \"Just saying no\" to SARS-CoV-2 positive donors.","text":["Emerging evidence to support not always \"Just saying no\" to SARS-CoV-2 positive donors.","We are gratified to see the broad discussion of our manuscript, \"Use of SARS-CoV-2 infected deceased organ donors: Should we always 'just say no?'\" and the companion manuscript by Shah et al., \"Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.\"(1,2) Our viewpoint argues that the risk of SARS-CoV-2 transmission from asymptomatic or minimally symptomatic donors is likely very low. For selected patients with imminently life-threatening organ failure, transplants from deceased donors with asymptomatic or mild SARS-CoV-2 infection may offer a favorable risk/benefit balance, although factors beyond transmission risk must also be considered.","Am J Transplant","Kates, Olivia S","Fisher, Cynthia E","Rakita, Robert M","Reyes, Jorge D","Limaye, Ajit P","32502313"],"abstract":["We are gratified to see the broad discussion of our manuscript, \"Use of SARS-CoV-2 infected deceased organ donors: Should we always 'just say no?'\" and the companion manuscript by Shah et al., \"Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.\"(1,2) Our viewpoint argues that the risk of SARS-CoV-2 transmission from asymptomatic or minimally symptomatic donors is likely very low. For selected patients with imminently life-threatening organ failure, transplants from deceased donors with asymptomatic or mild SARS-CoV-2 infection may offer a favorable risk/benefit balance, although factors beyond transmission risk must also be considered."],"journal":"Am J Transplant","authors":["Kates, Olivia S","Fisher, Cynthia E","Rakita, Robert M","Reyes, Jorge D","Limaye, Ajit P"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502313","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16119","weight":0,"_version_":1668804508786884608,"score":9.490897,"similar":[{"pmid":32400087,"title":"Use of SARS-CoV-2 infected deceased organ donors: Should we always \"just say no?\"","text":["Use of SARS-CoV-2 infected deceased organ donors: Should we always \"just say no?\"","In the context of a rapidly evolving pandemic, multiple organizations have released guidelines stating that all organs from potential deceased donors with SARS-CoV-2 infection should be deferred, including from otherwise medically eligible donors found to have mild or asymptomatic SARS-CoV-2 discovered on routine donor screening. In this manuscript, we critically examine the available data on the risk of transmission of SARS-CoV-2 through organ transplantation. The isolation of SARS-CoV-2 from non-lung clinical specimens, the detection of SARS-CoV-2 in autopsy specimens, previous experience with the related coronaviruses SARS-CoV and MERS-CoV, and the vast experience with other common RNA respiratory viruses are all addressed. Taken together, these data provide little evidence to suggest the presence of intact transmissible SARS-CoV in organs that can potentially be transplanted, specifically liver and heart. Other considerations including ethical, financial, societal, and logistical concerns are also addressed. We conclude that, for selected patients with high waitlist mortality, transplant programs should consider accepting heart or liver transplants from deceased donors with SARS-CoV-2 infection.","Am J Transplant","Kates, Olivia S","Fisher, Cynthia E","Rakita, Robert M","Reyes, Jorge D","Limaye, Ajit P","32400087"],"abstract":["In the context of a rapidly evolving pandemic, multiple organizations have released guidelines stating that all organs from potential deceased donors with SARS-CoV-2 infection should be deferred, including from otherwise medically eligible donors found to have mild or asymptomatic SARS-CoV-2 discovered on routine donor screening. In this manuscript, we critically examine the available data on the risk of transmission of SARS-CoV-2 through organ transplantation. The isolation of SARS-CoV-2 from non-lung clinical specimens, the detection of SARS-CoV-2 in autopsy specimens, previous experience with the related coronaviruses SARS-CoV and MERS-CoV, and the vast experience with other common RNA respiratory viruses are all addressed. Taken together, these data provide little evidence to suggest the presence of intact transmissible SARS-CoV in organs that can potentially be transplanted, specifically liver and heart. Other considerations including ethical, financial, societal, and logistical concerns are also addressed. We conclude that, for selected patients with high waitlist mortality, transplant programs should consider accepting heart or liver transplants from deceased donors with SARS-CoV-2 infection."],"journal":"Am J Transplant","authors":["Kates, Olivia S","Fisher, Cynthia E","Rakita, Robert M","Reyes, Jorge D","Limaye, Ajit P"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400087","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.16000","topics":["Prevention"],"weight":1,"_version_":1666714494909284352,"score":352.75586},{"pmid":32368850,"title":"Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.","text":["Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.","SARS-CoV-2 has rapidly become an unprecedented pandemic that has impacted society, disrupted hospital functions, strained healthcare resources and impacted the lives of transplant professionals. Despite this, organ failure and the need for transplantation continues throughout the United States. Considering the perpetual scarcity of deceased donor organs, Kates et al present a viewpoint that advocates for the utilization of COVID-19 positive donors in selected cases. We present a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The factors we consider include: 1) the risk of blood transmission SARS-CoV-2, 2) involvement of donor organs, 3) lack of effective therapies, 4) exposure of healthcare and recovery teams, 5) disease transmission and propagation, and 6) hospital resource utilization. While we acknowledge that transplantation fulfills the mission of saving lives, it is imperative to consider the consequences not only to our recipients, but also to the community and to healthcare workers, particularly in the absence of effective preventative or curative therapies. For these reasons, we believe the evidence and risks show that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies.","Am J Transplant","Shah, Malay B","Lynch, Raymond J","El-Haddad, Hanine","Doby, Brianna","Brockmeier, Diane","Goldberg, David S","32368850"],"abstract":["SARS-CoV-2 has rapidly become an unprecedented pandemic that has impacted society, disrupted hospital functions, strained healthcare resources and impacted the lives of transplant professionals. Despite this, organ failure and the need for transplantation continues throughout the United States. Considering the perpetual scarcity of deceased donor organs, Kates et al present a viewpoint that advocates for the utilization of COVID-19 positive donors in selected cases. We present a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The factors we consider include: 1) the risk of blood transmission SARS-CoV-2, 2) involvement of donor organs, 3) lack of effective therapies, 4) exposure of healthcare and recovery teams, 5) disease transmission and propagation, and 6) hospital resource utilization. While we acknowledge that transplantation fulfills the mission of saving lives, it is imperative to consider the consequences not only to our recipients, but also to the community and to healthcare workers, particularly in the absence of effective preventative or curative therapies. For these reasons, we believe the evidence and risks show that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies."],"journal":"Am J Transplant","authors":["Shah, Malay B","Lynch, Raymond J","El-Haddad, Hanine","Doby, Brianna","Brockmeier, Diane","Goldberg, David S"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368850","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/ajt.15969","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138496232849409,"score":321.70715},{"pmid":32359188,"title":"Strategies to halt 2019 novel coronavirus (COVID-19) spread for organ transplantation programs at the Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, China.","text":["Strategies to halt 2019 novel coronavirus (COVID-19) spread for organ transplantation programs at the Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, China.","During the coronavirus outbreak in China, our center performed 16 organ transplants (10 kidney, 4 liver and 2 lung transplants, from January 24 to March 11, 2020) harvested from deceased donors. Regarding the strategies to prevent infections of COVID-19, we implemented specific measures for the donor and recipient management, as well as prevention of hospital-acquired infections. All 16 organ recipients had a favorable outcome without COVID-19 infection. Our approaches aiming to interrupt the spread of coronavirus within the transplantation wards were successful and allowed us to maintain the transplantation program for deceased liver, kidney and lung recipients.","Am J Transplant","Wang, Yi","Liu, Huirong","Buhler, Leo H","Deng, Shaoping","32359188"],"abstract":["During the coronavirus outbreak in China, our center performed 16 organ transplants (10 kidney, 4 liver and 2 lung transplants, from January 24 to March 11, 2020) harvested from deceased donors. Regarding the strategies to prevent infections of COVID-19, we implemented specific measures for the donor and recipient management, as well as prevention of hospital-acquired infections. All 16 organ recipients had a favorable outcome without COVID-19 infection. Our approaches aiming to interrupt the spread of coronavirus within the transplantation wards were successful and allowed us to maintain the transplantation program for deceased liver, kidney and lung recipients."],"journal":"Am J Transplant","authors":["Wang, Yi","Liu, Huirong","Buhler, Leo H","Deng, Shaoping"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359188","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15972","locations":["China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138495292276737,"score":234.83293},{"pmid":32337825,"title":"High-Immunological Risk Living Donor Renal Transplant during the COVID-19 Outbreak: Uncertainties and Ethical Dilemmas.","text":["High-Immunological Risk Living Donor Renal Transplant during the COVID-19 Outbreak: Uncertainties and Ethical Dilemmas.","We describe the challenges of performing a high-immunological risk living donor renal transplant during the COVID-19 outbreak. A 42-year-old lady with end-stage renal disease from lupus nephritis had failed peritoneal dialysis due to pleuro-peritoneal leak, failed vascular access creation due to early thrombosis and had recurrent dialysis catheter malfunction. The transplant from her husband was ABO-incompatible and had positive B cell flow crossmatch with multiple donor-specific antibodies. Neither alternative donors nor paired exchange candidates were available. Priority access to deceased donors is limited and unpredictable.","Am J Transplant","Ho, Quan Yao","Chung, Shimin Jasmine","Gan, Valerie Huei Li","Ng, Lay Guat","Tan, Ban Hock","Kee, Terence Yi Shern","32337825"],"abstract":["We describe the challenges of performing a high-immunological risk living donor renal transplant during the COVID-19 outbreak. A 42-year-old lady with end-stage renal disease from lupus nephritis had failed peritoneal dialysis due to pleuro-peritoneal leak, failed vascular access creation due to early thrombosis and had recurrent dialysis catheter malfunction. The transplant from her husband was ABO-incompatible and had positive B cell flow crossmatch with multiple donor-specific antibodies. Neither alternative donors nor paired exchange candidates were available. Priority access to deceased donors is limited and unpredictable."],"journal":"Am J Transplant","authors":["Ho, Quan Yao","Chung, Shimin Jasmine","Gan, Valerie Huei Li","Ng, Lay Guat","Tan, Ban Hock","Kee, Terence Yi Shern"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337825","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15949","topics":["Prevention"],"weight":1,"_version_":1666138494283546625,"score":233.04451},{"pmid":32282982,"title":"Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","text":["Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices.","Am J Transplant","Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M","32282982"],"abstract":["COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices."],"journal":"Am J Transplant","authors":["Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282982","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15915","keywords":["clinical decision-making","epidemiology","guidelines","infectious agents - viral"],"locations":["US","US","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","remdesivir","tocilizumab","Azithromycin"],"topics":["Prevention"],"weight":1,"_version_":1666138491535228928,"score":221.59232}]}